Kodiak Sciences Inc.

NasdaqGM:KOD Rapport sur les actions

Capitalisation boursière : US$2.5b

Kodiak Sciences Gestion

Gestion contrôle des critères 3/4

Le PDG Kodiak Sciences est Victor Perlroth, nommé en Jun2009, a un mandat de 16.92 ans. La rémunération annuelle totale est $ 2.50M, composée du salaire de 31.7% et des bonus 68.3%, y compris les actions et options de la société. détient directement 4.68% des actions de la société, d'une valeur de $ 116.46M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 7.9 ans.

Informations clés

Victor Perlroth

Directeur général

US$2.5m

Rémunération totale

Pourcentage du salaire du PDG31.71%
Durée du mandat du directeur général16.9yrs
Propriété du PDG4.7%
Durée moyenne d'occupation des postes de direction4.8yrs
Durée moyenne du mandat des membres du conseil d'administration7.9yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Mar 27

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines

Summary Kodiak Sciences (KOD) surged after positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, demonstrating strong efficacy and risk reduction. KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Read the full article on Seeking Alpha
Article d'analyse • Oct 03

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Kodiak...
Seeking Alpha • Feb 24

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Summary Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027. KOD also recently partnered up with Nona Biosciences to enhance its ability to develop multi-target, human monoclonal antibodies. From a valuation perspective, I also think KOD trades near cash value with a strong runway into 2026. So, I believe it’s a decent “Buy” at these levels. Read the full article on Seeking Alpha
Article d'analyse • Dec 13

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 15

Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)

Summary Kodiak's stock surged 160% since September 2023, despite initial setbacks with tarcocimab in diabetic macular edema studies due to unexpected cataract development. Tarcocimab showed superiority over sham and better tolerability in a Phase 3 diabetic retinopathy trial, prompting Kodiak to resurrect the asset and initiate more pivotal trials. My previous recommendation was "sell" due to high risk and limited upside, but recent positive data and clinical advancements warrant a reassessment. KOD merits a "hold" ahead of key developments in their clinical trials, but this isn't for the faint of heart and works best within a barbell portfolio. Read the full article on Seeking Alpha
Article d'analyse • Aug 02

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Article d'analyse • Apr 17

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Article d'analyse • Dec 29

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Article d'analyse • Sep 09

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d'analyse • May 26

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d'analyse • Jan 04

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d'analyse • Sep 25

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 25

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Summary Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab, failed its very poorly designed clinical trial. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Shares have perked up since announcing the BEACON top line data. We are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve. The following segment was excerpted from this fund letter. Kodiak Sciences (KOD) A great example of companies that can perform in any environment is busted biotech world. One of the sectors undergoing the most pain in the recent year has been biotech, where we have invested in since 2004. Subsequent to the quarter end, we added a second company to our portfolio, and are actively engaged in researching more busted biotechs. Both our newest, Kodiak Sciences (KOD) and MEI Pharma (MEIP) have important regulatory catalysts in the very near future, and they have ample cash to get them through to the value inflection catalyst points. These are the types of names that can perform in any economic environment. The downside is protected by the cash position, and yes, while those cash positions are being spent on funding drug development, the long runways give us ample time to realize these value inflection milestones. We have been buyers of both companies as the market remains relatively indifferent to the looming regulatory updates. Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab (formerly KSI-301), failed its very poorly designed clinical trial. The company’s drug will fill a significant unmet medical need, particular for diabetic and elderly patients with macular edema who have given up going to their doctor every 1-2 months to get their eye injected with Regeneron’s EYLEA. Industry research suggests that well over half of patients have chosen deteriorating vision over the inconvenience of getting their eyes injected every 1-2 months. That’s where tarcocimab comes in. In recent trials, even the “failed” trial, it has shown that 60-70% of patients can go five months or longer while maintaining the same significantly improved vision. While there are multiple therapies available for these patients, there are none that have the durability of tarcocimab. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Tarcocimab seeks to disrupt a $13 billion industry, but more importantly, fill an important gap in the macular edema market. In our conversations with doctors actively engaged in research & clinical trials, they are very eager to have a drug that they can dose less frequently. Shares have perked up since announcing the BEACON top line data, but given they still trade below cash levels, they give us a lot of upside as subsequent trials prove out that the drug works. Given the rest of the pivotal trials will read out in the next nine months, we won’t have to wait long until tarcocimab is able to serve the significant unmet medical need, and file for approval with the FDA next year. We also expect a very important update to MEIP’s regulatory strategy which will alleviate market concerns on its own drug’s timeliness to market. While many catalysts depend on a healthy market environment to play out, these do not. They can perform in any economic scenario. Trying to predict with accuracy when the stock will reflect the underlying developments is impossible. But we do know that if you miss the most material upside days of certain stocks, the realized returns are significantly more mediocre. To the extent we are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve.
Seeking Alpha • Aug 07

Kodiak Sciences FQ1 2022 Earnings Preview

Kodiak Sciences (NASDAQ:KOD) is scheduled to announce FQ1 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$1.75 Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downward.
Article d'analyse • May 18

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 17

Kodiak Sciences: Potential For Comeback After Trial Setback

Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be worth $25.66 billion by 2028. Additional trial readouts using new dosing schedules such as diabetic macular edema, non-proliferative diabetic retinopathy, and treatment naive Wet-AMD are expected in 2023. Kodiak Sciences had $671.7 million in cash as of March 31, 2022, enough cash to fund operations for at least the next 12 months.
Seeking Alpha • Feb 25

Kodiak Sciences: KSI-301 Disappoints

Lead asset KSI-301 is being tested in six pivotal trials in retinal diseases including wet AMD, diabetic macular edema, retinal vein occlusion and non-proliferative diabetic retinopathy. Topline wet AMD data was released and KSI-301 failed to show non-inferiority against standard of care treatment Regeneron’s (REGN) Eylea in improvement in visual acuity. The study did not meet the primary endpoint. While KSI-301 appears safe and effective, it may not become a blockbuster.
Seeking Alpha • Feb 15

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept). Kodiak is attempting to prove non-inferiority in efficacy as shown by BCVA at 1 year vs. Eylea while showing the advantage of less frequent dosing. The first price target is $90 after positive data from the wet AMD Phase 3 trial this quarter or 70% upside potential in the stock (implied move from the options).
Article d'analyse • Jan 24

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d'analyse • Oct 11

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Today, we look at a biotech firm who is developing a portfolio of retina therapeutics built on the company’s antibody biopolymer conjugate platform. Kodiak has late-stage drug candidate targeting wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. A full investment analysis is presented in the paragraphs below.

Analyse de la rémunération des PDG

Comment la rémunération de Victor Perlroth a-t-elle évolué par rapport aux bénéfices de Kodiak Sciences?
DateRémunération totaleSalaireBénéfices de l'entreprise
Mar 31 2026n/an/a

-US$231m

Dec 31 2025US$2mUS$792k

-US$230m

Sep 30 2025n/an/a

-US$217m

Jun 30 2025n/an/a

-US$200m

Mar 31 2025n/an/a

-US$191m

Dec 31 2024US$2mUS$757k

-US$176m

Sep 30 2024n/an/a

-US$192m

Jun 30 2024n/an/a

-US$198m

Mar 31 2024n/an/a

-US$233m

Dec 31 2023US$3mUS$721k

-US$260m

Sep 30 2023n/an/a

-US$271m

Jun 30 2023n/an/a

-US$298m

Mar 31 2023n/an/a

-US$309m

Dec 31 2022US$3mUS$691k

-US$334m

Sep 30 2022n/an/a

-US$357m

Jun 30 2022n/an/a

-US$347m

Mar 31 2022n/an/a

-US$312m

Dec 31 2021US$113mUS$655k

-US$267m

Sep 30 2021n/an/a

-US$220m

Jun 30 2021n/an/a

-US$189m

Mar 31 2021n/an/a

-US$159m

Dec 31 2020US$9mUS$591k

-US$133m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$18mUS$526k

-US$47m

Rémunération vs marché: La rémunération totale de Victor ($USD 2.50M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 7.10M ).

Rémunération et revenus: La rémunération de Victor a augmenté alors que l'entreprise n'est pas rentable.

PDG

Victor Perlroth (51 yo)

16.9yrs
Titularisation
US$2,499,221
Compensation

Dr. Victor Perlroth, M.D., Co-Founded Kodiak Sciences Inc. in 2009 and also serves as its Chairman and President. Dr. Perlroth serves as a Director and Chief Executive officer of Kodiak Sciences Inc. since...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Victor Perlroth
Co-Founder16.9yrsUS$2.50m4.68%
$ 116.5m
John Borgeson
Executive VP10.3yrsUS$1.62m0.34%
$ 8.4m
Wayne To
Chief Technology Officer1.8yrspas de donnéespas de données
Dolly Chang
Chief Scientific Officer1.8yrspas de donnéespas de données
Hong Liang
Senior Vice President of Development8.6yrsUS$321.91kpas de données
Stephen Raillard
Senior Vice President of Chemical Development & Manufacturing3.3yrspas de donnéespas de données
Almas Qudrat
Chief Quality Officer6.3yrspas de donnéespas de données
J. Velazquez-Martin
Chief Medical Officer3.3yrspas de donnéespas de données
Laurent Ducay
Senior VP of Biologics Development & Manufacturingno datapas de donnéespas de données
4.8yrs
Durée moyenne de l'emploi
53yo
Âge moyen

Gestion expérimentée: L'équipe de direction de KOD est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Victor Perlroth
Co-Founder16.9yrsUS$2.50m4.68%
$ 116.5m
Robert Profusek
Lead Independent Director7.9yrsUS$179.30k0.016%
$ 398.6k
Felix Baker
Independent Director10.7yrsUS$92.80k0%
$ 0
Richard Levy
Independent Director7.9yrsUS$142.80k0.0016%
$ 39.8k
Bassil Dahiyat
Independent Director7.9yrsUS$147.80k0%
$ 0
Charles Bancroft
Independent Director6.1yrsUS$170.30k0.042%
$ 1.0m
David Boyer
Scientific Advisorno datapas de donnéespas de données
Michael IP
Scientific Advisorno datapas de donnéespas de données
Sunil Patel
Scientific Advisorno datapas de donnéespas de données
David Brown
Scientific Advisorno datapas de donnéespas de données
Carl Regillo
Scientific Advisorno datapas de donnéespas de données
Pravin Dugel
Scientific Advisorno datapas de donnéespas de données
7.9yrs
Durée moyenne de l'emploi
61yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de KOD sont considérés comme expérimentés (ancienneté moyenne 7.9 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/12 01:40
Cours de l'action en fin de journée2026/05/12 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Kodiak Sciences Inc. est couverte par 18 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Anita DushyanthBerenberg
Matthew LuchiniBMO Capital Markets Equity Research
Ying HuangBofA Global Research